drugset / Trial / NCT00335374
An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial
Timeline
- Start
- 2007-08
- Primary completion
- 2008-09
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pardoprunox | Small molecule | 12 mg | — |
| Subject | Pardoprunox | Small molecule | 42 mg | — |